A few days after the “Elena Beldiman” Emergency Hospital in Bârlad came into possession of several boxes of ampoules of neutralizing monoclonal antibodies, received as a donation from Italy to Romania, the doctors from Bârlad administered, for the first time, the treatment of a patient of 72 years, hospitalized with a moderate form of SARS-CoV-2 infection.
Last night, the management of the “Elena Beldiman” Emergency Hospital in Bârlad announced, through a press release published on its website and on the official social networking page, that, on Monday, October 25, the antibody treatment was administered for the first time. neutralizing monoclonal. According to experts, these are proteins produced in the laboratory that mimic the ability of the immune system to fight the new coronavirus, attach to the surface viral protein (Spike) and thus block the virus’s ability to attach to human cells. The monoclonal antibodies, used only for the treatment of moderate and severe cases to prevent the virus from entering the cell, were obtained through the EU Civil Protection Mechanism, the doses being donated to Romania by Italy, in gratitude for the help our country gave in the Lombardy region. , in the year 2020.
“The treatment with neutralizing monoclonal antibodies for SARS-CoV-2 was administered for the first time, last night, October 25, 2021, to a 72-year-old patient, admitted to the Infectious Diseases Department of our hospital, the procedure proceeding without problems at the ATI Department , under the guidance of Dr. Veaceslav Galit, ATI primary care physician. The patient who benefited from this treatment met the criteria provided in Order no. 2103 of October 12, 2021 on the protocol for the treatment of SARS-CoV-2 virus infection. The decision to administer neutralizing monoclonal antibodies to SARS-CoV-2 belongs to a committee of at least two Infectious Disease Physicians. In this case, during yesterday (Monday, no.), Following the evaluation of the patient’s status, the team formed by doctors Monica Aioanei and Luana Butiuc, both primary care physicians, decided that this treatment is appropriate. The patient had a mild form of COVID-19, but with great potential for aggravation in the absence of this treatment, this being in the first days after the onset of SARS-CoV-2 infection, the procedure being performed with her consent “, it is shown in the press release released last night.
“Neutralized monoclonal antibodies have specificity for SARS-CoV-2 virus protein S and, like other antiviral medications, efficacy depends on administration as early as possible after the onset of the disease, no later than the first seven days. Patients who may benefit from this treatment are those at significant risk of severe disease progression, this medication helping them to stop developing severe forms. According to Order no. 2,103 of 12 October 2021 on the protocol for the treatment of SARS-CoV-2 virus infection, eligibility criteria (EMA) – cumulative criteria: 1, 2, 3 and at least one of the risk factors are: 1. signing the informed consent; 2. light forms SO_2> 93% without supplementation of oxygen; 3. administration of monoclonal antibodies <7 days after the onset of symptoms; 4. risk factors for severe evolution (priority is given to people with several risk factors):
a. age> 65 years;
b. BMI > 30 kg/m^2;
c. severe cardiovascular disease, NYHA 4 heart failure, recent myocardial infarction, severe ischemic heart disease;
d. B.P.C.O.;
e. type 1 diabetes;
f. immunosuppressive therapy – biological therapies;
g. patients with organ or bone marrow transplantation;
h. patients with neoplasms or haematological diseases in therapy;
i. AIDS ”, it is also specified in the communiqué.
–
